Form 4: Esperion Therapeutics Director Reports Stock Transaction
Statement of Changes in Beneficial Ownership
Esperion Therapeutics, Inc. director J. Martin Carroll reported a transaction involving 79,873 shares of common stock.
Summary
- J. Martin Carroll, a Director at Esperion Therapeutics, Inc., has filed a Form 4 statement detailing a transaction.
- On May 28, 2026, 79,873 shares of common stock were acquired at a price of $0.
- Following this transaction, Mr. Carroll beneficially owns 177,523 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine disclosure of an insider stock transaction (likely an equity award) without immediate implications for the company's financial performance or strategic direction.
Positives
- Director J. Martin Carroll acquired a significant number of shares (79,873) at no cost, indicating a potential equity award or grant.
- The acquisition of shares at $0 suggests a form of compensation or incentive for the director.
Future Outlook
The acquired awards vest in full on the earlier of May 28, 2027, or the Issuer's next annual meeting of stockholders following May 28, 2026.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This specific filing indicates an equity award to a director, a common practice for executive compensation and alignment with shareholder interests.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | J. Martin Carroll granted a Limited Power of Attorney to Sheldon Koenig and Benjamin Looker to execute SEC forms on his behalf. | 06/01/2022 | Ensures compliance with SEC filing requirements for beneficial ownership reporting, even in the absence of Mr. Carroll's direct involvement in the filing process. |
Stakeholder Impact
- Shareholders: The acquisition of shares by a director at no cost can be viewed positively as it aligns director incentives with shareholder value, though the specific terms of the award are not detailed beyond vesting.
Next Steps
- The acquired awards will vest on the earlier of May 28, 2027, or the Issuer's next annual meeting of stockholders following May 28, 2026.
Key Dates
| Date | Description |
|---|---|
| 05/28/2026 | Transaction Date for acquisition of common stock. |
| 05/28/2027 | Vesting date for the acquired awards, or the Issuer's next annual meeting of stockholders following May 28, 2026, whichever is earlier. |
| 06/01/2026 | Date of signature for the Form 4 filing. |
| 06/01/2022 | Effective date of the Limited Power of Attorney granted by J. Martin Carroll. |
Keywords
Esperion Therapeutics, ESPR, Form 4, Director, Stock Transaction, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.